Calf Augmentation in Montgomery Alabama
This procedure offers a solution for those people that have underdeveloped calves or wish to augment them. The idea is to shape and size the calves by surgical insertion of implants. The implants are made of soft silicon and they come in different shapes and sizes. Before the operation your legs will be measured to select a proper implant for your needs. There is an alternative to implants. Calf augmentation can also be performed by liposuction of fat from other body parts and injecting it into the calves. This method is not suitable for people with no extra fat to be removed. Another problem is fat absorption that eventually occurs, sometimes creating not symmetric calves. Men and women can benefit from this procedure. Men usually want to increase the muscle bulk, giving them more masculine look and women wish to get more symmetrical appearance of their legs. This procedure also may help to correct some congenital defects, those include polio, spina bifida and clubfoot, all this conditions may be associated with undeveloped calves.
This procedure can be done with local or general anesthesia, and it usually lasts for an hour. During the operation the patient is laying on their back. A cut is made in the concavity behind the knee, then the skin is gently separated and a space is created. The implant is inserted above the muscles. After one leg is done the doctor performs the same on the other one. After the symmetry is confirmed the surgeon closes the cuts with stitches.
Every operation has its ricks. This one includes bleeding, infection and sometimes implants shrinkage and asymmetry.
After the surgery you may feel some degree of pain. Your doctor'll subscribe you for painkillers. At the first two days you'll be asked to raise your legs whenever you are sitting, this to reduce swelling. Afterwards, the bandages are removed and you are encouraged to walk more intensively to train your calve muscles. For about two weeks you'll fell like you're calves is been through excessive workout. Swelling and bruising also may appear, they are only temporary and will improve with time. You'll be able to go back to work after 7-10 days. You'll get detailed instructions from you're surgeon regarding the activities you should avoid, for example long walking, weight lifting and running. Usually, most of the patients are able to return to their daily activities after 4-6 weeks.
More Montgomery info...
Montgomery Eat Montgomery's diners tend to be very basic eaters. Lunch times are famous for what is called a "meat and three menu". That is where a restaurant, during the lunch hour, serves a meat course and three sides (vegetables or potatoes). It tends to be very filling (perhaps too filling)but reliable quantity and quality wise.
There seems to be a preference for corporate generic restaurants (Outback, Olive Garden, Red Lobster). If they have a franchise, Montgomery probably has one.
You need to understand a few southernisms when dining in Montgomery and these are applicable throughout the Alabama and Mississippi area.
Most restaurants serve "sweet" tea. That is tea that is more sweet that a two teaspoons of sugar. Ask for unsweet and sweeten it yourself.
Breakfast is served with biscuits (trust me, you will love them), never toast. They also serve grits with breakfast and it is considered appropriate to doctor them anyway that you like to eat them.
Bar-B-Que means that meat is slow cooked over a wood fire. Sauce is served on the side and I have seen the full range of sauces (mustard type, tomato based, Tex-Mex).
Montgomery is home for the Hyundai automobile plant. Look for several fine Korean and Pan Asian restaurants and interesting menu items.
Montgomery is in lower Alabama and you can expect, in some of the better restaurants, some Cajun influence.
Montgomery Learn
Alabama State University, [19].
Southern Christian University, [20].
Auburn University Montgomery, [21].
Faulkner University, [22]. Is a small Christian university.
Huntingdon College, [23]. A small United Methodist affiliated college.
Air University, [24]. AU is operated by the U.S. Air Force.
Plastic Surgery News...
- What are the new regulations? The Cells, Tissues and Organs (CTO) Regulations came into force on December 7, 2007, following extensive consultation, over a period of 11-years with the transplant community and Canadians. The safety of CTOs intended for transplantation is paramount.
- According to PharmaLive, the FDA has approved abatacept (Orencia®) for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients aged six years and above. It may be used as monotherapy or concomitantly with methotrexate (MTX), but should not be used concomitantly with tumour necrosis factor (TNF) antagonists or other biological therapy (e.g. anakinra).
This approval is based on the AWAKEN trial, which included 190 patients aged 6-17 years with moderately to severely active polyarticular JIA who had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). The first part was a 4-month, open-label lead-in phase in which patients received IV abatacept (10 mg/kg; maximum 1,000 mg) on Days 1, 15, 29 and every month thereafter. Those who achieved an ACR Pedi 30 response entered Period B - a six-month, double-blind phase involving randomisation to remain on abatacept (n=60) or to receive placebo (n=62) for six months. The primary endpoint of the study was time to occurrence of disease flare.
The main findings were as follows:
• In the lead-in phase, abatacept treatment resulted in a consistent improvement in ACR Pedi 30 across all JIA subtypes (oligoarticular extended - 59.3%; polyarticular-RF positive - 68.4%; polyarticular-RF negative - 64.3%; and systemic JIA with polyarticular course - 64.9%)
• The time to occurrence of disease flare was statistically significantly longer in patients treated with abatacept compared to patients treated with placebo compared with abatacept (p=0.0002) [no specific details given on magnitude of this difference]
• Patients treated with abatacept experienced fewer disease flares compared to placebo-treated patients (20% versus 53%, respectively, p<0.001)
• The risk of disease flare among patients continuing on abatacept was less than that for patients who withdrew from abatacept treatment (HR 0.31, 95% CI 0.16 to 0.59)
Please see the link above for further details.